[go: up one dir, main page]

CO5140102A1 - Formulacion farmaceutica en forma de pasta semisolida estabilizada para administracion oral que comprende omeprazol, de dos a cuatro agentes basificantes, un agente espesante y un vehiculo aceitoso hidrofobico - Google Patents

Formulacion farmaceutica en forma de pasta semisolida estabilizada para administracion oral que comprende omeprazol, de dos a cuatro agentes basificantes, un agente espesante y un vehiculo aceitoso hidrofobico

Info

Publication number
CO5140102A1
CO5140102A1 CO00012143A CO00012143A CO5140102A1 CO 5140102 A1 CO5140102 A1 CO 5140102A1 CO 00012143 A CO00012143 A CO 00012143A CO 00012143 A CO00012143 A CO 00012143A CO 5140102 A1 CO5140102 A1 CO 5140102A1
Authority
CO
Colombia
Prior art keywords
oral administration
pharmaceutical formulation
agents
omeprazol
basing
Prior art date
Application number
CO00012143A
Other languages
English (en)
Inventor
Keith Freehauf
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CO5140102A1 publication Critical patent/CO5140102A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una formulación farmacéutica para administración oral que comprende:(a) De 1% a 60% p/p de omeprazol,(b) De 0.1% a 2% p/p de dos a cuatro agentes basificantes,(c) De 1% a 3% p/p de un agente espesante, y(d) Un vehículo líquido aceitoso hidrofóbico que comprende:(i) Un aceite vegetal y(ii) Triglicéridos de ácidos grasos de cadena media y diésteres de propilen glicol de ácidos grasos de cadena media.
CO00012143A 1999-02-23 2000-02-22 Formulacion farmaceutica en forma de pasta semisolida estabilizada para administracion oral que comprende omeprazol, de dos a cuatro agentes basificantes, un agente espesante y un vehiculo aceitoso hidrofobico CO5140102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12125399P 1999-02-23 1999-02-23

Publications (1)

Publication Number Publication Date
CO5140102A1 true CO5140102A1 (es) 2002-03-22

Family

ID=22395498

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00012143A CO5140102A1 (es) 1999-02-23 2000-02-22 Formulacion farmaceutica en forma de pasta semisolida estabilizada para administracion oral que comprende omeprazol, de dos a cuatro agentes basificantes, un agente espesante y un vehiculo aceitoso hidrofobico

Country Status (31)

Country Link
US (1) US6316481B1 (es)
EP (1) EP1156806B1 (es)
JP (1) JP2002537337A (es)
KR (1) KR100701448B1 (es)
CN (1) CN1227009C (es)
AR (1) AR029615A1 (es)
AT (1) ATE263562T1 (es)
AU (1) AU771061B2 (es)
BG (1) BG65291B1 (es)
BR (1) BR0008403A (es)
CA (1) CA2362932C (es)
CO (1) CO5140102A1 (es)
CZ (1) CZ301647B6 (es)
DE (1) DE60009675T2 (es)
DK (1) DK1156806T3 (es)
EA (1) EA004683B1 (es)
ES (1) ES2216870T3 (es)
HK (1) HK1041650A1 (es)
HR (1) HRP20010615B1 (es)
HU (1) HU228181B1 (es)
IL (1) IL144131A0 (es)
ME (1) ME00864B (es)
NO (1) NO328863B1 (es)
NZ (1) NZ512771A (es)
PL (1) PL195783B1 (es)
PT (1) PT1156806E (es)
RS (1) RS50023B (es)
SK (1) SK286371B6 (es)
TW (1) TW587936B (es)
WO (1) WO2000050038A1 (es)
ZA (1) ZA200106104B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
AU6746501A (en) 2000-05-30 2001-12-11 Merial Ltd Methods for prevention of ulcers and improving physiological performance
EP1341523B1 (en) 2000-12-07 2013-01-23 Nycomed GmbH Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
DE10061135C1 (de) * 2000-12-07 2002-11-07 Byk Gulden Lomberg Chem Fab Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff
AU2002231654A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical paste comprising an acid-labile active ingredient
WO2004012659A2 (en) 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
GB2394895A (en) * 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
WO2005000269A1 (en) * 2003-06-26 2005-01-06 Cipla Limited Pharmaceutical formulations comprising a proton pump inhibitor
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006026829A1 (en) * 2004-09-09 2006-03-16 Metelli Pty Ltd Stable paste composition of enteric coated acid labile active agent and use thereof
CN101500553B (zh) * 2006-07-25 2012-04-18 维克塔有限公司 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法
CN101610754A (zh) * 2007-02-16 2009-12-23 Aska制药株式会社 含有微粒油性混悬液的药物组合物
WO2011011351A2 (en) * 2009-07-20 2011-01-27 Vetegen, Llc A stable pharmaceutical omeprazole formulation for oral administration
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
WO2013165468A1 (en) 2012-05-02 2013-11-07 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
US10064849B2 (en) 2012-05-02 2018-09-04 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
EP3057571B1 (en) * 2013-10-18 2019-03-06 Norbrook Laboratories Limited Proton pump inhibitor paste compositions
GB2524351B (en) * 2013-10-18 2016-12-14 Norbrook Lab Ltd Proton Pump Inhibitor Paste Compositions
PT3386507T (pt) 2015-12-08 2023-09-11 Luoda Pharma Ltd Métodos e composições para tratar úlceras gástricas
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018031935A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
WO2019113493A1 (en) 2017-12-08 2019-06-13 Adamis Pharmaceuticals Corporation Drug compositions
ES2723873B1 (es) * 2018-03-01 2020-05-13 Hernan Ma Carmen Batanero Medicamento combinado con omeprazol y vitamina B12
CN112972481A (zh) * 2021-03-18 2021-06-18 华农（肇庆）生物产业技术研究院有限公司 药物组合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255432A (en) 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
DK130287D0 (da) 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors

Also Published As

Publication number Publication date
HRP20010615A2 (en) 2002-12-31
KR20010102297A (ko) 2001-11-15
AU3368700A (en) 2000-09-14
NZ512771A (en) 2003-02-28
AU771061B2 (en) 2004-03-11
KR100701448B1 (ko) 2007-03-30
WO2000050038A1 (en) 2000-08-31
TW587936B (en) 2004-05-21
NO20014074D0 (no) 2001-08-22
YU50401A (sh) 2004-05-12
ATE263562T1 (de) 2004-04-15
ME00864B (me) 2008-09-29
CZ20013058A3 (cs) 2001-11-14
AR029615A1 (es) 2003-07-10
EP1156806A1 (en) 2001-11-28
CZ301647B6 (cs) 2010-05-12
HUP0200325A2 (en) 2002-06-29
CA2362932A1 (en) 2000-08-31
EP1156806B1 (en) 2004-04-07
EA200100905A1 (ru) 2002-02-28
DK1156806T3 (da) 2004-08-02
NO328863B1 (no) 2010-05-31
SK12062001A3 (sk) 2001-12-03
NO20014074L (no) 2001-08-22
PL195783B1 (pl) 2007-10-31
PT1156806E (pt) 2004-07-30
BG65291B1 (bg) 2007-12-28
ZA200106104B (en) 2002-12-24
PL350729A1 (en) 2003-01-27
HRP20010615B1 (en) 2011-03-31
BR0008403A (pt) 2002-01-29
SK286371B6 (sk) 2008-08-05
CN1227009C (zh) 2005-11-16
HUP0200325A3 (en) 2003-05-28
ES2216870T3 (es) 2004-11-01
HK1041650A1 (en) 2002-07-19
HU228181B1 (en) 2013-01-28
RS50023B (sr) 2008-09-29
BG105754A (en) 2002-03-29
IL144131A0 (en) 2002-05-23
DE60009675T2 (de) 2005-03-24
EA004683B1 (ru) 2004-06-24
CN1341022A (zh) 2002-03-20
CA2362932C (en) 2010-11-30
US6316481B1 (en) 2001-11-13
JP2002537337A (ja) 2002-11-05
DE60009675D1 (de) 2004-05-13

Similar Documents

Publication Publication Date Title
CO5140102A1 (es) Formulacion farmaceutica en forma de pasta semisolida estabilizada para administracion oral que comprende omeprazol, de dos a cuatro agentes basificantes, un agente espesante y un vehiculo aceitoso hidrofobico
DK0904064T3 (da) Orale farmaceutiske præparater indeholdende kønshormoner
AR046773A1 (es) Formulaciones farmaceuticas de bisfosfonatos
HUP0400566A2 (hu) Mátrixon diszpergált hatóanyagot tartalmazó gyógyászati készítmény
DK0750495T3 (da) Anvendelse af et lipofilt overfladeaktivt middel i et farmaceutisk præparat
DE69636413D1 (de) Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe
ES2165725T3 (es) Nanoemulsion a base de esteres grasos de acido fosforico, y sus utilizaciones en los ambitos cosmetico, dermatologico, farmaceutico y/u oftalmologico.
BRPI0009373B8 (pt) composições farmacêuticas orais contendo triglicerídeos de cadeia longa e tensoativos lipofílicos
ES2139800T3 (es) Preparaciones farmaceuticas liposomales inyectables.
ES2191862T3 (es) Composicion liquida que comprende un inhibidor de la vih proteasa y un acido graso de c12-c18.
ES2178997T3 (es) Composicion, particularmente cosmetica, que comprende una sapogenina.
ES2162031T3 (es) Preparaciones cosmeticas y/o farmaceuticas.
AR046642A1 (es) Composicion en forma de spray que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa, no volatil
DE60115402D1 (de) Neues selbstemulgierendes arzneistoffverabreichungssystem
AR029081A1 (es) Una composicion de enjuague con agentes de beneficio para el cuidado del cabello y la piel en emulsion multiple' agua en aceite en agua '
ES2175217T3 (es) Preparados de capsulas blandas que contienen ciclosporina.
ES2140512T3 (es) Composiciones farmaceuticas que contienen derivados de estaurosporina y un gliceridos polialquilenglicolico.
ES2044561T3 (es) Composiciones liquidas administrables por via oral a base de aceites comestibles.
RS52735B (en) APPLICATION OF A COMBINATION CONTAINING L-CARNITINE OR ALKANOIL L-CARNITINE, OIL-SOLUBLE OIL-BENZOQUINON AND OMEGA-3-POLYESATURATED FATTY ACID FOR PREPARATION OF NUTRITION OR MEDICINAL PRODUCTS
AR007873A1 (es) Composicion que comprende un componente hidrofilo, y la asociacion de un compuesto volatil y de un aceite siliconado fenilado y utilizacion de dichaasociacion
CO4790151A1 (es) COMPOSICIONES QUE COMPRENDEN UN INHIBIDOR DE LA PROTEASA DEL VIH COMO VX478 Y UN COMPUESTO DE VITAMINA E sOLUBLE EN AGUA COMO VITAMINA E - TPGS
WO1999039682A3 (en) Lipid mixtures and their use
DE60018715D1 (de) Pharmazeutische Zusammensetzung enthaltend Cyclosprin als aktiven Bestandteil
PT938339E (pt) Formulacoes para utilizacao topica
IT1292126B1 (it) Esteri cerosi arricchiti in acidi grassi omega-3 insaturi,loro preparazione ed uso